Free Trial

Matt Larew Analyst Performance

Analyst at William Blair

Matt Larew is a stock analyst at William Blair in the medical sector, covering 6 publicly traded companies. Over the past year, Matt Larew has issued 2 stock ratings, including buy and hold recommendations. While full access to Matt Larew's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matt Larew's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
10 Last 7 Years
Buy Recommendations
70.00% 7 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy70.0%7 ratings
Hold30.0%3 ratings
Sell0.0%0 ratings

Out of 10 total stock ratings issued by Matt Larew at William Blair, the majority (70.0%) have been Buy recommendations, followed by 30.0% Hold.

Exchange Coverage

ExchangePercentageCount
NYSE
66.7% of companies on NYSE
4 companies
NASDAQ
33.3% of companies on NASDAQ
2 companies

Matt Larew, an analyst at William Blair, currently covers 6 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Matt Larew of William Blair specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - OUTP/HM CRE
2 companies
33.3%
MED INSTRUMENTS
1 company
16.7%
MED - BIOMED/GENE
1 company
16.7%
MEDICAL SERVICES
1 company
16.7%
HOME HEALTH CARE SERVICES
1 company
16.7%

Matt Larew's Ratings History at William Blair

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Thermo Fisher Scientific Inc. stock logo
TMO
Thermo Fisher Scientific
8/18/2025Initiated Coverage$488.15Outperform
MaxCyte, Inc. stock logo
MXCT
MaxCyte
8/7/2025Downgrade$2.04Market Perform